The Cydem VT system combines multiple trusted Beckman Coulter Life Sciences technologies into one advanced platform that empowers lab managers with a far more effective, higher-throughput method for ...

The €60 million ($63 million) Shanbally, Cork expansion aims to increase production capacity. The facility will manufacture bulk drug substances and drug products and perform fill-finish services. The ...

Announced in 2021, the facility, named Modulus, is expected to be fully operational by 2026 and will create about 200 jobs locally. Modulus is Sanofi’s first "EVolutive vaccine facility (EVF)" outside ...

This website (the “Site”) is operated by Informa Connect, a trading division of the Informa Group. The parent company of the Informa Group is Informa PLC. Informa Connect (“Informa Connect”, “we” or ...

Articles In Color Color reprints are printed on 70# enamel paper and can be reproduced in color or in black and white. Color articles reprinted in black and white will be charged black and white ...

For the third quarter, Repligen reported revenue of $155 million, reflecting a 10% year-on-year increase. The organization cited its success in new modalities, sales in its contract development and ...

As of its 2023 guidance on combination and boundary products, the Australian Therapeutic Goods Administration (TGA) has provided context around key regulated product categories: Combination products ...

Multichain protein biotherapeutics such as bispecific molecules have been developed to treat cancer, neurological and ophthalmic disorders, and autoimmune and inflammatory diseases. Early successes ...

Biopharmaceutical giant GSK announced a site expansion at its Marietta, Pennsylvania site, where it will build a multipurpose manufacturing facility to produce sterile liquid vaccines and other ...

Biotechnology company Amgen is building a $1 billion drug substance manufacturing facility in Holly Springs, North Carolina, expanding its presence in the region with its second such facility. In ...

Indian pharmaceutical company Intas Pharmaceuticals signed a deal to acquire Udenyca, a bone marrow stimulant used to treat low white blood-cell counts in patients who take cancer medications. Accord ...

According to the firm, the plant will serve patients with rare, chronic, and genetic diseases including immunodeficiencies and bleeding disorders. Adding 125 jobs, the plant will increase the firm’s ...